about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Glax­o­SmithK­line, Vir gear up for EUA, cit­ing ear­ly PhI­II Covid-19 win with 'best-in-class' an­ti­body con­tender

5 years ago
R&D
Coronavirus

In the lat­est twist to IL-6 roller coast­er, Roche's Actem­ra fails PhI­II Covid-19 Vek­lury com­bo tri­al

5 years ago
R&D
Coronavirus

Aveo On­col­o­gy gets the long-await­ed green­light to mar­ket tivozanib — 9 years af­ter fil­ing its first NDA

5 years ago
Pharma
FDA+

Mer­ck inks Keytru­da deal with Sur­face On­col­o­gy; Rock­et Phar­ma­ceu­ti­cals gets ex­pe­dit­ed re­view of gene ther­a­py for rare ...

5 years ago
News Briefing

Chi­na's Yisheng­Bio chron­i­cles come­back sto­ry in Hong Kong IPO while plot­ting big moves in in­fec­tious dis­eases, can­cer

5 years ago
Financing
China

Take­da goes all in with build-to-buy play, pick­ing up Mav­er­ick and its clin­ic-ready T cell en­gagers for $525M

5 years ago
Deals

Cy­to­Dyn tries to squeeze pos­i­tive news out of a failed Covid-19 study — and shares take a beat­ing

5 years ago
R&D

Roche with­draws Tecen­triq in blad­der can­cer amid FDA's sweep­ing re­view on ac­cel­er­at­ed ap­provals

5 years ago
Pharma
FDA+

The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

5 years ago
Weekly

Fo­cus­ing on the bright side, FDA OKs Roche's Actem­ra for rare lung dis­ease de­spite PhI­II flop

5 years ago
Pharma
FDA+

Af­ter three years of courtship (and turn­downs), Mer­ck pounced on the first glance of clin­i­cal da­ta in $1.85B Pan­dion ...

5 years ago
Deals

Covid-19 roundup: EMA starts rolling re­view of Rus­si­a's Sput­nik V; No­vavax says shot is 51% ef­fec­tive against vari­ant ...

5 years ago
Coronavirus

Amid back of­fice con­sol­i­da­tion, Gilead ax­es 179 jobs in Cal­i­for­nia

5 years ago
Pharma

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

5 years ago
Deals

As al­lo­gene­ic cell ther­a­py ap­proach­es flour­ish, Cen­tu­ry loads up $160M to scale iP­SC plat­form for CAR-T, CAR-NK

5 years ago
Financing
Cell/Gene Tx

A spot­light schiz­o­phre­nia drug in Neu­ro­crine's $2B Take­da deal flunks its first ma­jor test. But it's not giv­ing up ...

5 years ago
R&D

Fi­bro­Gen shares skid low­er as a sur­prise ad­comm rais­es risks on roxa OK

5 years ago
FDA+

Pre­ci­sion in­flam­ma­tion drugs? Yale spin­out Ar­ti­zan clinch­es $11M and Bio­haven deal to sin­gle out bad bac­te­ria

5 years ago
Financing
Deals

Four IPOs and a SPAC pitch a new slate of mi­cro­bio­me, can­cer and in­flam­ma­to­ry drugs to Wall Street

5 years ago
Financing

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

5 years ago
Deals
China

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

5 years ago
Pharma

The fu­ture of mR­NA, J&J's vac­cine ad­comm, Mer­ck­'s $1.85B au­toim­mune bet and more

5 years ago
Weekly

Covid-19 roundup: US se­cures 100,000 dos­es of Eli Lil­ly's an­ti­body cock­tail; Mer­ck­'s $356M sup­ply deal on hold as FDA ...

5 years ago
Coronavirus

With dust set­tled on ac­tivist at­tack, Lau­rence Coop­er leaves Zio­pharm to a new board

5 years ago
People
First page Previous page 54555657585960 Next page Last page
A service from the Financial Times